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1. Introduction  
Pancreatic cancer remains to be one of the most lethal solid tumours of the gastrointestinal 
tract with a 5-year survival rate lower than 5%. It is characterised by late diagnosis, 
aggressive local invasion, early systemic dissemination and resistance to chemo- and radio-
therapy. At the time of diagnosis more than 85% of patients have already developed 
metastasis and are therefore not eligible for local treatments with curative intention such as 
surgery or radiotherapy. Chemotherapy with Gemcitabine is the mainstay of palliative 
treatment with modest antitumour effects in these patients.  
The process of cancer initiation, progression and metastasis remains to be poorly 
understood. Little is known about the development of metastatic progression and the 
dissemination of cells from the primary tumour site into distant organs. A better 
understanding and thorough investigation of the biology behind pancreatic cancer invasion 
and metastasis is urgently needed. Current concepts and emerging fields of research in 
pancreatic cancer metastasis shall be discussed in this chapter. 
2. Mechanisms of metastatic evolution  
Metastasis has been conventionally viewed as the last step in a cumulative process of 
genetic alterations within cells of a primary tumour mass. For metastatic cells to progress, 
they have to acquire distinct properties such as loss of cell adhesion, acquisition of an 
invasive potential, ability of intravasation, transport through the circulation, extravasation, 
formation of micro-metastases, and finally the ability to induce an angiogenic switch to form 
macro-metastasis (Coghlin & Murray, 2010). This hypothesis has been recently challenged 
by several groups (Bernards & Weinberg, 2002; Weinberg, 2008; Klein, 2008). An alternative 
model is proposed that considers the genetic alterations accumulated at the initial stages of 
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tumour’s evolution to be sufficient to promote the metastasis process. Two distinct models 
arising from this hypothesis are discussed in the following section. 
2.1 Metastasis: Progression models 
2.1.1 Late metastasis (linear progression) model  
This model is based on Leslie Fould’s description of a step-wise progression of 
morphological abnormalities accompanying cancer (Klein, 2009). It places selection of 
genetic and epigenetic modifications mostly inside the established primary tumour for 
competitive fitness. After multiple rounds, the cells may be able to proliferate relatively 
autonomously at a competitive rate and seed to secondary metastatic niche sites (Fig.1). Late 
disseminating cells are expected to be genetically identical to the parental cells of the 
primary tumour and should be subject to similar tumour cell targeting therapeutic 
modalities (Klein, 2008, 2009; Coghlin & Murray, 2010).  
 
Fig. 1. Models of metastasis evolution: in the late metastasis model, cells acquire genetic and 
epigenetic modifications mainly in the primary tumour site of the organ. Mutated cells 
disseminate within the blood stream into the final metastatic niche. However, in the early 
metastasis model cells accumulate genetic alterations at distant sites and thus diverge from 
the primary tumours at both genetic and epigenetic levels. 
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2.1.2 Early metastasis (parallel progression) model 
In contrast to the late metastasis model, here tumour cells are believed to leave the primary 
site quite early up-on activation of factors such as Twist (master regulator of embryonic 
morphogenesis) with a major role in metastasis during tumourigenesis (Yang et al., 2004) 
and to diverge genetically at ectopic sites whereby they generate a further cascade of 
metastatic cells (Fig.1). Owing to the different selection pressures at different niches 
(metastastic sites) and inherent genetic instability of tumour cells, parallel progression 
predicts greater variation among metastatic founder and primary tumour cells. 
Consequently they may respond differently to systemically administered drugs (Klein, 2008, 
2009; Coghlin & Murray, 2010).  
2.2 Progression of metastasis in pancreas cancer  
Whether the dismal prognosis of patients with pancreatic cancer compared to those with 
other cancer types is a consequence of late diagnosis or early dissemination to distant organs 
is still debated. In a study performed by Yachida et al., data generated from sequencing of 
the genomes of seven pancreatic cancer metastases, were used to evaluate any clonal 
relationship between primary and their corresponding metastatic cancers. After 
development of the parental clone, clonal evolution continues within the parental site giving 
rise to distant metastases. They provided evidence that primary pancreatic cancers contain a 
mix of geographically and genetically distinct sub-clones, each harbouring large numbers of 
cells that are present within the primary tumour years before the metastases become 
clinically apparent (Yachida et al., 2010). Additional studies led to estimation of at least three 
time-scales associated with tumour progression: the time between tumour initiation to 
establishment of the founder cell of the parental clone (average 10 years, T1); the sojourn 
time between the arising parental clone and its acquisition of metastatic potential (average 
6.8 years, T2); and the time from metastatic dissemination to patient’s death (average 2.7 
years, T3) (Yachida et al., 2010; Lubeck, 2010). Unfortunately, the vast majority of cancer 
patients are diagnosed within the last two years of tumour development. The great 
challenge would rather be the detection of these lesions during or shortly after T1, but 
before T2-T3 i.e., the seeding of metastases.  
3. The host and the tumour micro-environment 
Malignant cells do not exist in isolation, but are rather intensely communicating with the 
surrounding cells in their micro-environment such as microvessel endothelial cells, 
macrophages, fibroblasts, bone-marrow-derived cells etc. These interactions significantly 
contribute to tumour proliferation, local invasion and distant metastasis. 
3.1 Pancreatic stellate cells: Role in pancreatic cancer metastasis 
The transition of the pancreatic stellate cells (PSC) from a quiescent to an ‘’activated’’ or 
‘’myofibroblastic’’ state plays a key role in various pathogenic disorders of the exocrine 
pancreas. In quiescent state, PSC express intermediate filament proteins desmin, glial 
fibrillary acidic protein (GFAP), vimentin and nestin. Up-on activation, induced by various 
stimuli such as injury, PSC attain other markers such as smooth muscle actin (SMA), and 
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interstitial collagen type I. Therefore, activated PSC constitute a major source for 
development of tissue fibrosis attributed to e.g. chronic pancreatitis and pancreatic 
adenocarcinoma (PDAC) (Omary et al., 2007; Hwang et al., 2008). 
Intense fibrotic reaction referred to as tumour desmoplasia is a hallmark of pancreatic 
cancer (Cruickshank et al., 1986; Hwang et al., 2008; Bachem et al., 2008; He et al., 2007; 
Erkan et al., 2010) whereby infiltrating carcinoma cells get surrounded by a dense fibrotic 
stroma consisting mainly of collagen types I and III as well as fibronectin (Imamura et al., 
1995; Bachem et al., 2008). PSC, attracted by pancreatic cancer cells, get activated by various 
paracrine stimulants and growth factors, such as platelet-derived growth factor (PDGF) 
rendering them motile and proliferative, fibrogenic mediators such as transforming growth 
factor beta (TGFǃ) which stimulate matrix synthesis resulting in this desmoplastic reaction, 
cytokines such as interleukin Il-1, Il-6, Il-8, and tumour necrosis factor alpha (TNFǂ) (Omary 
et al., 2007; Bachem et al., 2008). Among the key implications of the desmoplastic reaction 
are the promotion of survival and prevention of apoptosis of pancreatic tumour cells 
through direct interaction with extra-cellular matrix (ECM), increased production of matrix 
metalloproteases (MMP) and serine proteases such as members of the plasminogen activator 
system (Vaquero et al., 2003; Edderkaoui et al., 2005). 
Additionally, soluble factors produced by PSC themselves stimulate the proliferation and 
survival of pancreatic cancer cells. Hwang et al. have shown that co-injection of PSC along 
with pancreatic cancer cells increases tumour incidence, size, and metastasis in an 
orthotopic model of pancreatic cancer (Hwang et al., 2008). In addition, combined 
inoculation of human pancreatic cancer and stellate cells in a xenograft model was shown to 
promote tumour growth and progression as compared to inoculation of tumour cells alone 
(Bachem et al, 2008). In another study, significantly elevated expression of urokinase 
plasminogen activator (uPA) as well as fibroblastic uPA receptor (uPAR) was correlated 
with liver metastasis of human pancreatic cancers, indicating a possible role of stromal 
fibroblasts in promoting pancreas cancer dissemination. Co-culturing of peri-tumour 
fibroblasts with metastatic BxPC3 pancreas cancer cells activates matrix metalloprotease-2 
(MMP-2) and up-regulates uPAR expression, along with elevated expression of integrin 
ǂ6ǃ1 in BxPC3 cells. This suggests a possible interaction between integrins of cancer cells 
and the uPAR of the stromal fibroblasts along the uPAR-uPA-MMP-2 cascade (He et al, 
2007). Moreover, Buechler et al. demonstrate a de novo transcriptional regulation of uPAR 
mRNA by the hypoxia-inducible factor-1 (HIF-1), accompanied by an increased rate of 
hypoxia-induced metastasis (Buechler et al., 2009). Taken all together, pancreas cancer 
growth and progression are accelerated via an orchestrated functional interaction among 
carcinoma cells and stellate/stromal fibroblast cells. 
3.2 Tumour-associated macrophages: Role in cancer metastasis 
Tumour-associated macrophages (TAM) are bone-marrow-derived cells capable of 
promoting tumour invasion, angiogenesis, immune evasion, and migration (Allavena et al., 
2008; Coghlin & Murray, 2010). In normal tissues, pathogenic challenge or wounding results 
in the local expression of a variety of growth factors e.g. colony stimulating factor 1 (CSF1) 
also known as macrophage CSF, granulocyte-macrophage CSF (GM-CSF), TGFǃ1, in 
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addition to various chemokines such as CCL2, CCL7, CCL8, CCL3 CCL4. Such a milieu 
recruits circulating monocytes and stimulates their differentiation into macrophages 
(Pollard et al., 2004).  
At the primary tumour site, hypoxia-related factors and oncogenic induction of pro-
inflammatory mediators mentioned above also result in the recruitment of macrophages 
(TAM) as well as mobilisation of bone-marrow-derived progenitor cells. TAM may there-
after stimulate angiogenesis by expressing factors such as vascular endothelial growth 
factor (VEGF), and angiopoietin 1/2 (ANG1-ANG2). Moreover, they recruit 
hematopoietic cells (e.g., mast cells or neutrophils) which exert similar functions (Pollard 
et al., 2004).  
Along with activated stromal cells, TAM act synergistically with malignant cells to degrade 
the ECM and release growth factors favouring invasiveness. TAM promote invasion by 
producing proteases that digest the basement membrane and remodel the stromal matrix. 
Additionally, they produce multiple growth factors which stimulate the growth of the 
tumour cells themselves (Pollard et al., 2004).  
4. Local invasion and distant metastasis 
4.1 The epithelial-to-mesenchymal transition (EMT) 
Epithelial-to-mesenchymal transition (EMT) describes a biologic process in which polarised 
epithelial cell under-go various bio-chemical modifications and ultimately gain 
mesenchymal characteristics i.e., enhanced migration and invasiveness, increased resistance 
to apoptosis, as well production of ECM components (Kalluri & Neilson, 2003). A proposal 
has been made which classifies EMT into three different sub-types. Type 1 EMT is associated 
with implantation and embryonic gastrulation and gives rise to the mesoderm, endoderm 
and to mobile neural crest cells. On the other hand, type 2 EMT promotes organ fibrosis 
mediated by inflammatory cells. The last type of EMT, type 3, is associated with cancer 
progression and metastasis (Kalluri & Weinberg, 2009).  
The EMT process is characterised by decreased expression of Epithelial cell-cell junction 
molecule E-cadherin along with increased expression of non-epithelial cadherins mostly N-
cadherin and acquisition of mesenchymal cytoskeleton markers such as vimentin and SMA, 
accompanied by nuclear beta-catenin accumulation (Shintani et al., 2006; Yang & Weinberg, 
2008; Coghlin & Murray, 2010). Tumour cells undergoing EMT are typically seen at the 
invasive fronts of primary tumours. These cells may eventually enter into subsequent steps 
of the invasion-metastasis cascade namely intravasation, transport through the circulation, 
extravasation, formation of micro-metastases, and colonisation (Fig. 2) (Thiery, 2002, 2003; 
Fidler & Poste, 2008; Brabletz et al., 2001).  
EMT is initiated by extra-cellular signals e.g. hepatocyte growth factor (HGF), fibroblast 
growth factor (FGF), epidermal growth factor (EGF), and TGFǃ which activate multiple 
EMT-inducing transcription factors notably Snail, Slug, zinc finger E-box binding homoebox 
(ZEB1) and Twist (Savagner et al., 2001; Lee et al., 2006; Shintani et al., 2006; Kalluri & 
Weinberg, 2009). Activation of EMT cascade also involves the disruption of cell-cell 
adherens junctions and integrin-mediated adhesion in the ECM.  
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Fig. 2. The role of EMT in cancer metastasis: epithelial tumour cells lose their polarity and 
detach from the basement membrane. This situation is referred to as carcinoma in situ. 
During the EMT process, primary epithelial tumour cells undergo various modifications 
whereby they lose their epithelial markers and acquire mesenchymal properties, i.e. digest 
the basic membrane and invade the surrounding tissue. The onset of angiogenic switch and 
establishment of abnormal tumour neo-vasculature favours the intravasation of metastatic 
cells into the blood-stream. Only a small fraction of disseminated tumour cells (DTC) 
survive in circulation, extravasate into distant organs and form single cell or small tumour 
colonies also called micro-metastases. DTCs or micro-metastases could remain dormant for 
a prolonged period of time until they eventually switch to angiogenic macroscopic 
metastatic lesion and become clinically apparent (Folkman & Kalluri, 2004; Almog et al., 
2009). Interestingly, metastatic lesions derived from carcinomas demonstrate the epithelial 
characteristic of their primary tumour of origin suggesting that according to this model 
mesenchymal to epithelial transition (MET) occur during tumour colonisation in the distant 
sites.  
4.2 Matrix metalloproteases (MMP) 
MMP are a family of enzymes involved in degradation of ECM components e.g. collagen 
and fibronectin (Jimenez et al., 2000). MMP of either malignant cells or induced fibroblasts 
at the invasive front are thought to mediate cancer invasion and metastasis via disruption of 
tumour cell adhesion molecules and degradation of basement membranes and other matrix 
components.  
Immunohistochemical studies have demonstrated over-expression of active MMP-2, MMP-9 
(Gress et al., 1995; Koshiba et al., 1998), MMP-7 and MMP-11 (Bramhall et al. 1997) in 
tumours with lymph node metastasis. The involvement of MMP-1 in promoting 
angiogenesis and metastatic spread has been recently linked to pancreatic cancer (Abdollahi 
et al., 2007). Using an orthotopic mouse model of pancreatic cancer, the MMP inhibitor 
Batimastat was shown to improve the survival and to reduce growth of tumours in mice 
implanted with HPAC, a moderately differentiated pancreatic cancer cell line (Zevros et al., 
1997). Recent work in multiple carcinomas suggests a crucial role of transcriptional 
regulators Snail and Slug in the regulation of E-Cadherin expression (Gavert & Ben-Ze’ev, 
2008). In pancreatic cancer, Slug is shown to promote the invasiveness of tumour cells 
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through up-regulating ECM proteins such as MMP-9 along with remodeling of the actin 
cytoskeleton (Zhang et al., 2011).  
4.3 Growth factor expression patterns in pancreas metastasis  
Among its pleiotropic effects TGFǃ was shown to potently induce EMT in different 
tumours. TGFǃ signalling in pancreatic cancer is often attenuated because of alterations in 
components of this pathway (Jonson et al., 2001). Using genetic array data, genes responsive 
to TGFǃ in pancreas cancer cell line PANC-1 are depicted to be involved in ECM 
remodeling, cell motility, adhesion, angiogenesis, cell cycle, proliferation and apoptosis 
(Gaspar et al., 2006). Negative regulation of E-cadherin necessary for EMT has been 
observed in PANC-1 cultures (Halder et al., 2005), and has been associated with lymph node 
metastasis (Pignatelli et al., 1994). Regulation of JAG1 by TGFǃ on the array is interesting 
because its gene product Jagged1 (Notch ligand), is influenced by TGFǃ in cultured 
epithelial cells. Notch signalling is an important cell signalling pathway involved in 
regulation of the balance between cell proliferation, differentiation, and apoptosis. Notch-1 
has been reported to induce nuclear factor κB (NFκB) promoter activity (Jang et al., 2004). 
Down-regulation of Notch-1, and consequently of NFκB and MMP-9 inhibits invasion of 
pancreatic cancer cells through matrigel (Wang et al., 2006). Inhibition of TGFǃ signalling 
reduces PDAC growth and invasiveness (Gaspar et al., 2006). 
TGFǃ signalling is altered in human pancreas cancer cells with one half of tumours showing 
allelic deletions or inactivating mutations of the Smad4 gene. These cells show an enhanced 
TGFǃ-mediated EMT as determined by increased vimentin expression and decreased beta-
catenin and E-cadherin expression. TGFǃ-mediated invasion is suppressed in Smad4 intact 
cells in vitro which show reduced dissemination in an orthotopic pancreatic cancer model 
(Zhao et al., 2008). Interestingly, cells with an intact Smad pathway reveal reduced 
activation of signal transducer and activator of transcription (STAT3). STAT3 is 
constitutively activated in various carcinomas and plays a pivotal role in regulating cell 
growth, cell survival and angiogenesis (Yu & Jove, 2003; Abdollahi et al., 2004). Inhibition of 
STAT3 phosphorylation by Smad4 suppresses TGFǃ-mediated invasion and metastasis of 
pancreatic cancer cells (Zhao et al., 2008). Therefore, reconstitution of Smad4 activity or 
suppression of STAT3 down-stream signalling constitutes attractive targets to inhibit TGFǃ-
induced EMT and pro-metastatic effects.  
Other factors known to be frequently over-expressed in several human malignancies and to 
be associated with invasion of tumour cells are the insulin-like growth factor I receptor (IGF-
IR) and HGF receptor c-Met. IGF-IR over-expression and excessive activation are associated 
with malignant transformation, tumour aggressiveness, and protection from apoptosis 
(Macaulay, 1992;  Sell et al., 1995). Over-expression of IGF-IR, reported in pancreatic 
carcinomas, is regulated by AKT activation thereby promoting invasiveness of human 
pancreatic cells (Tanno et al., 2001). Furthermore IGF-IR and c-Met co-operate 
synergistically to induce migration and invasion of human pancreatic carcinoma cells (Bauer 
et al., 2006). 
EGFR is over-expressed in approximately 90% of pancreatic carcinoma and is associated 
with poor prognosis. Blocking of EGFR signalling in various animal models reduces growth 
and spread of pancreas carcinoma (Baselga & Arteaga, 2005). Of note, low-molecular weight 
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tyrosine kinase inhibitors targeting EGFR such as erlotinib are the only class of targeted 
inhibitors so far demonstrating additional mild benefits when combined with gemcitabine 
versus gemcitabine mono-therapy in treatment of metastatic PDAC (Moore et al., 2007). 
Accordingly, erlotinib is the only targeted therapy currently approved for clinical use in 
PDAC. In extension of this work, dual inhibition of EGFR signalling using erlotinib (alone or 
in combination with gemcitabine) and of hedgehog signalling with cyclopamine were 
shown to inhibit tumour growth, increase apoptosis, and suppress the dissemination of 
pancreatic cancer cells (Feldman et al., 2007; Mimeault et al., 2005, Hu et al., 2007). 
4.4 Hypoxia and angiogenesis  
The presence of significant hypoxia in pancreatic cancers has been long suspected due to the 
relatively poor contrast agent enhancement of pancreatic cancer lesions suggestive of hypo-
vascular regions in e.g. computer tomography (CTscans, Megibow, 1992). Koong et al. 
directly detected hypoxia in pancreas cancer by placement of intra-tumoural needles 
measuring tissue oxygen levels at the time of resection in seven operable pancreatic cancer 
patients (Koong et al., 2000). Hypoxia renders tumours more aggressive, and resistant to 
chemo- and radio-therapy (Garcea et al., 2006, Abdollahi et al. 2005). Therefore, the 
combination of desmoplastic reaction and strong intra-tumoural hypoxia synergistically 
contribute to the inherent resistance of pancreas cancer against cancer therapies such as 
chemotherapy. 
For a tumour or any other tissue to grow above the size of 1mm3, recruitment of new vessels 
is required. This process is termed tumour angiogenesis (Folkman, 1971). The “angiogenic 
switch” is considered a hallmark of cancer and refers to the phenomenon in which the 
balance of pro- and anti-angiogenic factors is shifted towards the pro-angiogenic state 
(Hanahan & Folkman, 1996; Abdollahi et al., 2005; Hanahan & Weinberg, 2011). 
Nevertheless, the hypo-vascular phenotype of pancreatic tumours observed by contrast 
enhanced non-invasive imaging techniques misled the research in this field to precept that 
angiogenesis is not playing a key role in development of PDAC. The role of an angiogenic 
micro-environment in development of pancreatic cancer is only recently reported 
(Abdollahi et al., 2007). It is shown that the angiogenic state gradually switches from normal 
pancreas (off) to chronic inflammation (pancreatitis, intermediate) to primary pancreatic 
tumour and distant metastases (on). These data indicate that aberrant pro-angiogenic micro-
environment might contribute to the 19-fold increased cancer risk in patients with chronic 
pancreatitis (Abdollahi et al., 2007). Although several angiogenic factors have been 
associated with PDAC, most of the studies have so far focused on VEGF reporting its pivotal 
role in stimulation of endothelial cell proliferation, migration, gene activation, and apoptosis 
evasion (Dvorak et al., 1995; Ferrara, 1999, Abdollahi et al. 2005). VEGF is a dimeric cytokine 
with members including VEGF-A (most common isoform), VEGF-B, VEGF-C, VEGF-D and 
VEGF-E. VEGF-A exerts its effects on target endothelial cells via binding to its specific trans-
membrane tyrosine kinase receptors VEGFR-1 and VEGFR-2 (Ferrara, 1999; Dvorak, 2002). 
Hypoxia has been shown to stimulate VEGF transcription in pancreatic carcinoma cell lines. 
This requires Src activation and leads to increased steady-state levels of HIF-1ǂ and 
increased phosphorylation of STAT3. Expression of VEGF in STAT3 or HIF-1ǂ dominant 
negative mutants is significantly reduced. Together, STAT3 and HIF-1ǂ are both required 
for maximum transcription of VEGF mRNA following hypoxia (Gray et al., 2005).  
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4.4.1 Local invasion and lymph-angiogenesis 
Tumour cell dissemination may follow several patterns e.g. local invasion, lymphatics, 
hematogenous spread, or direct seeding of body cavities or surfaces (Rubbia-Brandt et al., 
2004). The recent discovery of lymphatic endothelium-specific markers such as VEGFR-3, 
LYVE-1 and lymph-angiogenic growth factors VEGF-C and VEGF-D has allowed better 
understanding of tumour-associated de novo lymph-angiogenesis – the generation of new 
lymphatic vessel - in the metastatic process (Kopfstein et al., 2007). The expression of VEGF-
C and VEGF-D is reported in a variety of human tumours and is correlated with markers of 
lymphatic vessel density (LVD), lymph node metastasis and poor prognosis (Sleeman et al., 
2009). Tumour-associated lymphatic vessels have been reported to occur both peri- and/or 
intra-tumourally with the latter case correlating with lymph node metastasis and prognosis. 
In contrast to most tumours, in pancreatic carcinoma the correlation between lymph- 
angiogenesis marker and worse prognosis is still controversially debated (Sleeman &  
Thiele, 2009).  
VEGF-C and VEGF-D are the most extensively studied factors that enhance tumour-induced 
lymph-angiogenesis and lymph node metastsasis (Thiele & Sleeman, 2006). VEGF-C is 
highly expressed in pancreatic cancer tissue and cell lines, while its receptor VEGFR-3 is 
expressed on cancer stromal cells. Thus, local tumour growth is promoted via paracrine 
simulation of VEGFR-3 expressing stromal cells leading to the entry of cancer cells into peri-
tumoural lymphatics (Schneider et al., 2006). Kofstein et al. have used Rip1VEGF-D 
transgenic mouse model of pancreatic ǃ-cell carcinogenesis to investigate the functional role 
of VEGF-D in inducing lymph-angiogenesis and tumour progression. They show that 
VEGF-D expressing tumours exhibit peri-tumoural lymphangiogenesis along with 
lymphocyte accumulations and hemorrhages, with frequent lymph node and lung but not 
hepatic metastases (Kofstein et al., 2007). Similar to VEFG-D, transgenic expression of VEGF-
C in Rip1VEGF-C model induces peri-tumoural, but not intra-tumoural lymph-
angiogenesis, and promoting lymph node metastasis without affecting blood vessel 
angiogenesis (Mandriota et al., 2001).  
Additional mechanisms are described to be involved in tumour lymph-angiogenesis e.g. 
insertion of endothelial cells into the existing lymphatic endothelium. The existence of 
lymphatic progenitor cells was attributed to the CD34+ CD133+ VEGFR-3+ expressing cells 
which could differentiate into cells expressing vascular and lymphatic endothelial cell 
markers (Salven et al., 2003). Moreover, expression of chemokine receptor CCR7 by tumour 
cells enables them to migrate to lymphatic endothelial cells expressing the cognate ligand 
CCL21. Interestingly, CCR7+ tumour cells could produce CCR7 ligands and migrate with 
the lymphatic fluid in a process referred to as autologous chemotaxis (Sleeman et al., 2009) 
4.4.2 VEGF and liver metastasis 
VEGF expression is closely related with micro-vessel density and seems to be a crucial 
indicator for liver metastasis and a poor prognosis in pancreatic adenocarcinoma (Seo et al., 
2000). Elevated VEGF levels are correlated with tumour size (Itakura et al., 1997) and liver 
metastasis (Seo et al., 2000). Others have shown that the presence of TGFǃ in the tumour 
micro-environment plays an important role in enhancing liver metastasis by modulating the 
capacity of angiogenesis and immunogenicity (Teraoka et al., 2001). Histological studies in 
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pancreatic cancer patients often show invasion into large veins and dissemination into the 
liver. This is accompanied by elevated expression of MMP-2 and MMP-9 (Nagakawa et al., 
2002). VEGF levels were shown to be markedly elevated in liver metastases as compared to 
non-tumour bearing liver. However, no correlation was found in VEGF expression between 
liver metastases and primary pancreatic carcinoma (Tawada et al., 2008).  
4.5 Role of chemokines in pancreas metastasis  
Chemokines are low molecular-weight peptide ligands involved in the trafficking of 
leukocytes and other motile cells (Murphy et al., 2000; Mellado et al., 2001). Their receptors 
are cell-surface, seven trans-membrane G protein-coupled receptors. Many chemokines have 
more than one ligand and can activate more than one receptor.  
4.5.1 Role of the chemokine receptor CXCR4 in pancreas metastasis  
CXCR4 has been detected on many leukocytes such as lymphocytes, monocytes, natural 
killer cells, as well as on vascular smooth muscle cells, endothelial cells, and astrocytes 
(Caruz et al., 1998; Wegner et al., 1998; Zhang et al., 1998; Balkwill, 2004). The chemokine 
CXCL12, originally termed stromal derived factor 1 (SDF-1), is a ligand for CXCR4. In 
normal adult, the interplay between CXCR4 and CXCL12 is critical for homing and retention 
of hematopoietic progenitor cells in the bone-marrow (Richard & Blay, 2008). High levels of 
CXCR4 are expressed by these progenitor cells, which in turn get attracted to CXCL12 
produced by stromal cells in specialised bone-marrow niches (Aiuti et al., 1997). Stem cells 
and some other differentiated cells in the pathological contexts of inflammation and tissue 
regeneration or repair are also influenced by the chemo-attractant potency of CXCL12. It is 
postulated that metastatic cancer cells subvert the physiologic function of CXCR4/CXCL12 
in controlling cell migration and homing.  
It has been shown that CXCL12/CXCR4 axis promotes progression and dissemination of 
various carcinomas. CXCR4 is over-expressed at high levels on cells of solid epithelial 
cancers including pancreas, and CXCL12 concentrates in fluid-filled cavities through which 
many cancers disseminate and at tissue sites where metastases develop (Richard & Blay, 
2008). Most human pancreatic cancer tissues and more than 50% of pancreatic cell lines stain 
positively for CXCR4 and express CXCR4 protein, respectively. Chemotaxis induction of 
human pancreas carcinomas, as well as stimulation of their proliferation and survival is 
induced by CXCL12 (Figure 3) (Marchesi et al., 2004; Koshiba et al., 2000). Kayali and 
colleagues have shown in an interferon gamma-non-obese diabetic mouse model that 
CXCL12 stimulates the phosphorylation of AKT, mitogen-activated protein kinase (MAPK), 
and Src in pancreatic duct cells, and that it influences ductal cell migration. Blocking the 
CXCL12/CXCR4 axis in this model leads to a reduced proliferation and increased apoptosis 
of pancreatic ductal cells (Kayali et al., 2003). Moreover, CXCR4 small molecule antagonists, 
such as TN14003, were shown to inhibit migration of human pancreatic cancer cells in vitro 
via alteration of MAPK phosphorylation (Mori et al., 2004). 
Recently, a study in 30 patients with pancreatic cancer was initiated to evaluate the 
expression of CXCL12 and CXCR4 in tumour tissues, normal pancreas, and regional lymph 
nodes. They report low CXCL12 levels in tumour tissues as compared to para-cancerous 
tissues, normal pancreas, and lymph nodes. On the other hand, levels of CXCR4 in tumour 
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tissues were markedly higher. Additionally, they depict a significant correlation among the 
expression of CXCL12/CXCR4 axis and that of lymph node metastases (Cui et al., 2010).  
 
Fig. 3. Dissemination of tumour cells via the CXCL12/CXCR4 axis. Chemokine signalling 
enhances tumour invasion, tissue remodelling and tumour resistance to apoptotic stimuli. 
Moreover, pancreatic tumour cells expressing CXCR4 migrate towards the gradient of 
CXCL12 released by distant organs such as lymph nodes, lung, and liver. Hence, in addition 
to facilitating tumor invasion, the chemokine guidance plays a critical role in spread of 
tumour cells from primary sites to form distant metastases.  
Several factors regulating the expression of CXCR4 in tumour cells reside within the tumour 
micro-environment. It has been shown that hypoxia via hypoxia-inducible factor 1 alpha 
(HIF1ǂ) upregulates CXCR4 (Staller et al., 2003). Accordingly, CXCR4 expression was found 
to be enhanced in CXCR4-positive cell lines cultured under hypoxic conditions (Marchesi et 
al., 2004). As mentioned above matrix metalloproteases such as MMP-2 and MMP-9 have 
been associated with haematogenous tumour spreading. Chemokine and MMP activity 
seems to be intertwined as treatment of tumour cell lines with CXCL12 were shown to 
activate MMPs and trigger tumour cell invasion (Marchesi et al., 2004). Gao et al. proposed a 
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crucial role for PSC in promoting the invasion of human pancreatic cancer cells through the 
CXCL12/CXCR4 axis (Gao et al., 2010). In addition, CXCL12 was shown to protect CXCR4-
positive pancreatic tumour cells from serum starvation-induced death or interleukin-1-
induced damage via decreasing their rate of apoptosis (Marchesi et al., 2004). Together, 
these data suggest an important role for chemokine signalling in matrix-remodelling, 
tumour invasion and enhanced cell survival by evading apoptotic stimuli.  
4.6 Influence of PPAR on pancreas metastasis  
Peroxisome proliferator-activated receptors (PPAR) are ligand-activated transcription 
factors belonging to the super-family of nuclear hormone receptors (Isseman & Green, 1990). 
Three major sub-types have been described so far: PPAR-ǂ, PPAR-ǃ/ǅ, and PPAR-Ǆ. PPAR-
Ǆ has been recently shown to be over-expressed in pancreatic cancers (Eibl et al., 2004). 
Troglitazone, a synthetic PPAR-Ǆ agonist/ligand, leads to G1 cell cycle accumulation and 
inhibits cellular proliferation in vitro (Itami et al., 2001). Implantation of PANC-1 tumours in 
nude mice shows significant inhibition of tumour growth treated with pioglitazone, another 
PPAR-Ǆ agonist (Itami et al., 2001). In another study, both ciglitazone and 15d-prostaglandin 
J2 (15d-PGJ2) were shown to inhibit the growth of four tested pancreatic cancer lines. 
Treatment with 15d-PGJ2 significantly suppresses pancreatic cancer cell invasiveness which 
is accompanied by a reduction of MMP-2 and MMP-9 protein levels and activity 
(Hashimoto et al., 2002). The anti-tumour activity on pancreas cancer cell invasion was in 
part attributed to the influence of PPAR-Ǆ ligands on the serine protease urokinase-type 
plasminogen activator (uPA) and its receptor (uPAR) (Sawai et al., 2006). In addition, 
synthetic PPAR-Ǆ agonists may impede metastasis formation via interference with 
chemokine signalling by decreasing CXCR4 expression levels (Richard & Blay, 2008). Of 
note, data generated with synthetic PPAR ligands known as PPAR “agonists” or 
“antagonists” are not always matching data generated by genetic knock-down studies 
suggesting that binding of synthetic ligands may induce additional or different effects, by 
e.g. release of endogenous ligands (Lee et al., 2003; Plutzky, 2003). In this context, anti-
metastatic but not anti-proliferative effects were also reported after treatment of pancreas 
cancer with a synthetic PPAR-Ǆ ligand (T0070907), known to be a specific PPAR-Ǆ 
antagonist (Nakajima et al., 2008). In contrast, PPAR-Ǆ agonists were shown to inhibit the 
growth of pancreas tumours via downregulation of VEGF and thus inhibition of tumour 
angiogenesis (Dong et al., 2009). This is in line with previous observations suggesting an 
involvement of PPAR-Ǆ signalling in the angiogenesis process (Panigrahy et al. 2002). 
PPAR-ǂ and PPAR-ǃ/ǅ, the two other members of this family were also proposed to play a 
critical role in tumor growth and angiogenesis (Park et al., 2001, Abdollahi et al. 2007; 
Müller-Brüsselbach et al., 2007; Wang et al., 2006; Kaipainen et al., 2007; Panigrahy et al. 
2008). In particular, PPAR-ǃ/ǅ expression levels were shown to be gradually increased from 
normal pancreas to chronic pancreatitis to primary tumor and distant metastasis of pancreas 
cancer (Abdollahi et al. 2007). Moreover, PPAR-ǃ/ǅ was found to play a central role within 
a network of genes that govern the angiogenic switch process. Accordingly, targeted 
removal of PPAR-ǃ/ǅ in tumor microenviroment via implantation of wt-tumors in PPAR-
ǃ/ǅ knockdown mouse resulted in impaired tumor growth and angiogenesis (Abdollahi et 
al. 2007). This data are consistent with other studies reporting on impaired wound healing 
and reduced body fat; both processes known to be angiogenesis dependent (Peters et al., 
2000; Michalik et al., 2001).  
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4.7 Genomic studies 
Recent advances in high-through put sequencing analysis have improved our 
understanding of genetic alterations in pancreatic cancer. In 2008 Jones et al. reported on 
sequencing protein-coding exons from 20,735 genes in 24 pancreatic cancers. They found 
that pancreatic cancer contains an average of 63 genetic alterations, the majority of which 
were point mutations that could be assigned to a core set of 12 cellular signalling pathways 
being altered in 67% to 100% percent of pancreatic cancers. These include, apoptosis (100% 
affected), DNA damage control (83%), regulation of G1/S phase transition (100%), 
hedgehog signalling (100%), homophilic cell adhesion (79%), integrin signalling (67%), c-Jun 
N-terminal kinase signalling (96%), K-Ras signalling (100%), regulation of invasion (92%), 
small GTP-ase Ras-independent signalling (79%), TGF-ǃ signalling (100%), and Wnt/Notch 
signalling (100%). Although these pathways partially over-lap in the majority of the patients 
tested, every individual tumour might reveal variations in the alterations observed in 
pathway components. This perspective likely applies to most of epithelial cancers, and 
explains the heterogeneity within individual genes and within individual tumours (Jones et 
al., 2008). 
Shi et al. have established a highly metastatic pancreatic cancer line SW1990HM from intra-
splenic injection of SW1990 tumor cells. Gene expression profiles of SW1990HM and 
SW1990 cells show 40 metastasis-related genes expressed with a 3-fold difference. From the 
40 genes 32.5% are assigned to be adhesion and ECM-related genes, namely matrix 
metalloproteases (MMP-10, MMP-9, MMP-7), E-cadherin tumour suppressor gene (CDH1), 
and the golgi enzyme glycosyltransferase (MGAT5). Another 30% are found to be cell-
growth and proliferation-related such as insulin growth factor 1 (IGF1), interleukin 8 
receptor beta (IL8RB), integrin A7 (ITGA7), murine double minute oncogene (MDM2), 
mesenchymal epithelial transition factor (MET), somatostatin receptor 2 (SSTR2), and VEGF 
(Shi et al., 2009).  
Thakur and colleagues have utilized Ela-c-myc transgenic mice, described previously to 
develop acinar carcinoma (50%) as well as mixed ductal and acinar cell carcinoma (50%), to 
show spontaneous metastasis to the liver (Liao et al., 2006, 2007; Thakur et al., 2008). 
Microarray analyses revealed up-regulation of genes involved in DNA replication, cell 
proliferation and cell cycle regulation, chromosome organization, and signal transduction. 
Many genes are related to the maintenance of chromosomal structure and integrity such as 
mini-chromosome maintenance 2 (MCM2), MCM5; MCM10; structural maintenance of 
chromosome 211 (SMC21l), SMC41l, SMC51l, RAD51, and BRCA1.  
In alignment with these data expression analysis of two established cell lines (HPAC and 
PANC1) in terms of their patterns of invasiveness, reveals significant increase in the 
expression of DNA repair genes. DNA copy number of BRCA1 and RAD51 genes is also 
found to be increased in tissues isolated from metastatic pancreas cancer in comparison to 
normal tissue from the respective sites (Mathews et al., 2011).  
Thakur et al also described elevated expression levels of IGFBP1 and Serpin1 in liver 
metastatic tissues as compared to primary pancreatic tumours and normal pancreas. Both 
genes are also known to be over-expressed in highly metastatic human pancreatic cell lines 
(PANC28, CoLo357fg, L3.6pl) in comparison to less metastatic cell lines (PANC1 and 
BxPC3) (Thakur et al., 2008). 
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5. Peri-neural invasion 
Tumour peri-neural invasion (PNI), i.e., the neurotropism of pancreatic tumour cells and 
their metastasis into the peri-neural space of peripheral nerves constitutes a unique feature 
of pancreatic ductal adenocarcinoma (PDAC). PNI is associated with poor prognosis in 
patients due to the fact that tumour cells disseminating along nerve fascicles are spared by 
surgery and could therefore contribute to the local recurrence of pancreatic cancer (Marchesi 
et al., 2010; Pour et al., 2003). The human pancreas harbours a large amount of neural tissue 
and is innervated by the autonomic nervous system through plexi from the celiac and 
superior mesenteric artery ganglia. In majority of pancreatic cancer patients (~90%) tumor 
cells infiltrate intra-pancreatic nerves, with involvement of about 70% of extra-pancreatic 
nerves. Neural infiltration by cancer cells along with the accompanying ultimate nerve 
damage serve to cause the characteristic severe pain in pancreatic cancer patients (Pour et 
al., 2003). Morphologic changes at the migration front include characteristic increased neural 
density and hypertrophy and clustering of malignant cells around the neuritis (Ceyhan et 
al., 2008; Dai et al., 2007). 
5.1 Mediators and molecular mechanisms of PNI  
Investigation of many pathologic sections reports an increase in the size of nerve fibres in 
the vicinity of pancreatic tumours, suggesting the necessity of neurotropic factors, growth 
factors, and axonal guidance molecules as key players in this aspect (Chedotal et al., 2005; 
Chilton et al., 2006). Major neurotropic factors, such as neurotropins (NT) which include 
nerve growth factor (NGF), brain-derived nerve growth factors (BDNF), NT-3, NT-4, and 
NT-5, are over-expressed in tumour cells and intra-tumoural nerves (Ketterer et al., 2003). 
Other factors including hematopoietic colony stimulating factors (G-CSF) and their 
receptors (G-CSFR and GM-CSFRǂ) have also been shown to be expressed at high levels in 
pancreatic tumour micro-environment and to be associated with induction of pain. To this 
end, injection of anti-sera containing neutralising anti-bodies against G-CSF and GM-CSF 
receptors in a murine model of tumour-induced bone pain prevents hyperalgesia and 
reduces the number of nerves branching into the skin surrounding the tumour 
(Schweizerhof et al., 2009). In addition, myelin associated glycoprotein (MAG or Siglec-4a), 
expressed by Schwann cells bind to mucin 1 (MUC1) enriched on the surface of pancreas 
tumour cells (Swanson et al., 2007). 
5.2 Chemokines and tumour PNI  
CX3C chemokine receptor 1 (CX3CR1) also known as the fractalkine receptor or G-protein 
coupled receptor 13 (GPR13) are known to be involved in leukocyte adhesion and 
migration. Cells expressing this receptor bind to corresponding ligand CX3CL1 expressed 
on the surface of neurons, nerve fibres, and activated endothelial cells (Marchesi et al., 2010). 
In contrast to normal pancreas cells, tumour cells over-express CX3CR1 which in turn 
stimulates PNI. A large fraction (~90%) of pancreatic cancer biopsies are CX3CR1 positive 
and high receptor expression is associated with prominent PNI in pancreas cancer (Marchesi 
et al., 2008). A novel CX3CR1 antagonist has been recently developed and shown to block 
the cell adhesion along the CX3CL1/CX3CR1 axis (Dorgham et al., 2009). Thus, interference 
with CX3CL1/CX3CR1 signalling poses an attractive approach in prevention of PNI. Figure 
4 illustrates some molecular mechanisms known to be involved in PNI. 
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Fig. 4. Molecular mechanisms of PNI: Tumour cells expressing CX3CR1 and MUC-1 
infiltrate the peri-neural space and adhere to CX3CL1 and Siglec-4a on the surface of neural 
cells. Both cell types secrete neurotropins which are crucial for sustaining growth and 
survival of both cell types. Pain perception is influenced upon the interaction between CSF 
secreted by tumour cells and their receptors CSFR on the surface of neural cells. 
A novel method has been developed by Abiatari et al. to monitor ex vivo PNI of PDAC 
tumor cells into surgically resected rat vagal nerves. Genome-wide transcriptional analyses 
deciphered a set of differentially regulated genes in high versus low invasive pancreas 
tumour cells. Kinesin family member 14 (KIF14) and Rho-GDP dissociation inhibitor ǃ 
(ARHGDIǃ) are among two candidate PNI genes identified. Increased expression of both 
proteins was confined to tumour cells invading the peri-neural niche in pancreatic tumour 
patients. Finally, functional knock-down of KIF14 and ARHGDIǃ resulted in altered PNI of 
tumour cells (Abiatari et al., 2009). These data indicate that a better molecular 
characterization of the PNI process is a prerequisite for development of targeted therapies 
aiming to inhibit the pancreatic cancer metastasis.  
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6. Pancreatic cancer stem cells 
An emerging field of cancer research attempts to identify cellular hierarchies among the 
tumour cell population. Evidence are provided for tumor cells with self-renewing and stem-
cell-like characteristics within solid tumours termed tumour-initiating cells (TICs) or cancer 
stem cells (CSC) (Reya et al., 2001; Al Hajj et al., 2003; Singh et al., 2004 O’Brien et al., 2007; 
Ricci-Vitani et al., 2007). It is hypothesised that CSC undergo EMT at the invasive front of 
primary tumours and migrate to colonise new tissue. The concept of ‘’migrating CSC’’ 
describes a cancer stem cell which possess both an element of stemness and mobility 
(Brabletz et al., 2005). The relationship between CSC and pancreatic cancer progression was 
investigated by Li et al. (2007). They have chosen cancer stem cell markers based on 
previous work on breast cancer stem cells. These include the cell surface markers CD44, 
CD24, and epithelial-specific antigen (ESA). CD44+ CD24+ ESA+ pancreatic CSC 
demonstrate typical features observed in adult stem cells such as the ability of self-renewal, 
generation of differentiated progeny, and activation of developmental signalling pathways 
such as sonic hedgehog (Li et al., 2007). They further reported that only hundred human 
CD44+ CD24+ ESA+ pancreatic CSC are required to generate subcutaneous tumours in 50% 
of immuno-compromised SCID mice.  
CD133 is yet another potential marker discussed to be characteristic for pancreatic CSC 
(Hermann et al., 2007). They showed that the capacity of cells to form primary tumours 
following orthotopic implantation in nude mice was exclusive to the CD133+ sub-population 
which also demonstrated inherent resistance to gemcitabine chemotherapy. Further studies on 
highly metastatic pancreatic cancer cell line L3.6pl identified two sub-sets of tumour cells 
based on the expression of CXCR4 receptor (Miller et al., 2008). Depletion of CXCR4 subset of 
CD133+ pancreatic CSCs precluded the formation of spontaneous liver metastases. In line with 
above mentioned data, CXCL12 appears to be the strongest inducer of migration in CD133+ 
cancer cells in vitro. A component of the therapeutic plant Boswellia serrata, acetyl-11-keto-ǃ-
boswellic acid (AKBA), has been shown to down-regulate CXCR4 expression in pancreatic 
tumour cells and suppress cancer cell invasion (Park et al., 2011). Negative staining of 
cytokeratin epithelial cell marker in the CD133+ (in contrast to CD133- CSC) indicated EMT 
phenotype, thereby explaining their invasive potential (Mani et al., 2008). Blocking of the 
CXCL12/CXCR4 interaction with the CXCR4 non-peptidic antagonist reduces the spread of 
CD133+/CXCR4+ invasive pancreas cancer cells (Hermann et al., 2007).  
Correlation between CD133 expression and lymph node metastasis in pancreatic cancer was 
investigated by Maeda et al. Immunohistochemical assessment of samples from 80 patients 
with PDAC after surgery revealed <15% CD133+ tumours cells per tumour in only 60% of 
specimen (48/80) suggesting a low frequency of these cells in PDAC. However, if CD133+ 
cells were detected they were cytokeratin negative and were confined to the glandular 
structures in the periphery of tumours. CD133 expression significantly correlated with 
clinicopathological parameter including VEGF-C expression, lymphatic invasion and lymph 
node metastasis (Maeda et al., 2008).  
7. Conclusion  
A better comprehension of the processes governing the formation of metastases is critical 
towards development of more advanced cancer treatment modalities. Various theories of 
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metastatic cancer progression have lately emerged. In contrast to late dissemination model 
early dissemination and parallel evolution of tumours in primary vs. metastatic sites impact 
current perception of tumour heterogeneity and consequently will impact the development 
of targeted cancer treatment strategies. The emergence of novel sequencing and high-
through put genetics methods will hopefully assist cancer research in defining the relevance 
of each model in pancreatic cancer development.  
Acquisition of multiple genetic aberrations in the tumour cells is crucial for initiation of 
cancer. However, the communication of tumour cells with tumour-micro-environment is a 
prerequisite for successful tumour progression towards metastatic disease. Therefore, a 
better understanding of molecular mechanism underlying the orchestrated action between 
tumor cells and its micro-environmetal participants such as stellate cells, endothelial cells, 
pericytes, immune cells and bone-marrow derived cells are urgently needed. The 
contribution of angiogenesis, EMT, cytokine/chemokine axis, neurotropism, hypoxia and 
tissue remodelling in development of pancreatic cancer are still in an early stage. Further 
research is needed to elaborate the molecular characteristics of specific niches such as liver 
vs. lymph nodes in development of PDAC metastases. In contrast to dynamic models 
considering tumour cell plasticity as the pivotal force behind its ability to gain specific traits 
when exposed to e.g. EMT or hypoxia stimuli, the existence of deterministic hierarchies 
among pancreatic tumour cells as proposed by the emerging tumour stem cell community 
remain elusive. In conclusion, a concerted multidisciplinary effort is needed to identify 
novel targets, rationally design therapies and ultimately improve the treatment of this 
devastating disease.  
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